| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Runx2 and Osterix mRNA expression can be significantly increased by KI-7 (1 μM; 5–21 days; mesenchymal stem cells) [1]. Cell viability is significantly increased at both differentiation stages by KI-7 (1 μM; 15–21 days) [1]. It has been demonstrated that KI-7, a positive allosteric modulator of the A2B adenosine receptor in MSCs, enhances the in vitro osteoblast differentiation-promoting actions of both adenosine and synthetic orthosteric A2B adenosine receptor agonists. KI-7, BAY 60-6583, and NECA all significantly increased the production of IL-6. Even though this effect only becomes noticeable at day 21, KI-7 amplifies the effects of orthotopic agonists at both differentiation stages [1].
|
|---|---|
| References |
| Molecular Formula |
C23H18N2O2
|
|---|---|
| Molecular Weight |
354.401225566864
|
| Exact Mass |
354.136
|
| CAS # |
1489263-00-4
|
| PubChem CID |
73350966
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
523
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C(NC1C=CC=CC=1)=O)C1=CN(CC2C=CC=CC=2)C2C=CC=CC=21
|
| InChi Key |
MQMGZFRIEZRHHJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H18N2O2/c26-22(23(27)24-18-11-5-2-6-12-18)20-16-25(15-17-9-3-1-4-10-17)21-14-8-7-13-19(20)21/h1-14,16H,15H2,(H,24,27)
|
| Chemical Name |
2-(1-benzylindol-3-yl)-2-oxo-N-phenylacetamide
|
| Synonyms |
KI7 KI 7 KI-7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~705.42 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL | |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL | |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05872906 | RECRUITING | Device: Acupuncture | Ultrasound Imaging de qi of Acupuncture |
China Medical University Hospital | 2023-03-06 | Not Applicable |
| NCT01395511 | COMPLETED | Device: Acupuncture | Whiplash Associated Disorder (WAD) | Kyunghee University Medical Center | 2009-12 | Phase 2 |
| NCT04374084 | UNKNOWN STATUS | Other: Moxibustion plus Cupping | COVID-19 Convalescence |
Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 2020-05-10 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
